Discover open access scientific publications

Search, annotate, share and cite publications

Publications by S. Stilgenbauer

Immunoglobulin Heavy Chain Variable Gene Usage and (Super)-Antigen Drive in Chronic Lymphocytic Leukemia

Clinical Cancer Research

Cancer Research

Oncology

2010

English

Ofatumumab Monotherapy in Fludarabine-Refractory Chronic Lymphocytic Leukemia: Final Results From a Pivotal Study

Haematologica

Hematology

2015

English

MDM2 Promotor Polymorphism and Disease Characteristics in Chronic Lymphocytic Leukemia: Results of an Individual Patient Data-Based Meta-Analysis

Haematologica

Hematology

2014

English

Fixed-Duration Venetoclax Plus Obinutuzumab Improves PFS and Minimal Residual Disease Negativity in Patients With Previously Untreated CLL and Comorbidities

Hematological Oncology

English

High Efficacy of Venetoclax Plus Obinutuzumab in Patients With Complex Karyotype (Ckt) and Chronic Lymphocytic Leukemia (Cll): A Prospective Analysis From the Cll14 Trial

Hematological Oncology

English

Autologous Stem Cell Transplantation in First Remission Significantly Prolongs Progression-Free and Overall Survival in Mantle Cell Lymphoma

Hematological Oncology

English

Effect of Dose Modifications on Response to Duvelisib in Patients With Relapsed/Refractory CLL/SLL in the Duo Trial

Hematological Oncology

English

An Improved Benefit-Risk Profile of Duvelisib in Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Who Received 2 or More Prior Therapies

Hematological Oncology

English

Samd14/Neurabin-I as BCR-Antigens of Primary Central Nervous System Lymphoma

Hematological Oncology

English

Bendamustine (B), Followed by Obinutuzumab (G) and Venetoclax (A) in Patients With Chronic Lymphocytic Leukemia (Cll): Cll2-Bag Trial of the German CLL Study Group (Gcllsg)

Hematological Oncology

English

Amanote Research

Discover open access scientific publications

Search, annotate, share and cite publications

Publications by S. Stilgenbauer

Immunoglobulin Heavy Chain Variable Gene Usage and (Super)-Antigen Drive in Chronic Lymphocytic Leukemia

Ofatumumab Monotherapy in Fludarabine-Refractory Chronic Lymphocytic Leukemia: Final Results From a Pivotal Study

MDM2 Promotor Polymorphism and Disease Characteristics in Chronic Lymphocytic Leukemia: Results of an Individual Patient Data-Based Meta-Analysis

Fixed-Duration Venetoclax Plus Obinutuzumab Improves PFS and Minimal Residual Disease Negativity in Patients With Previously Untreated CLL and Comorbidities

High Efficacy of Venetoclax Plus Obinutuzumab in Patients With Complex Karyotype (Ckt) and Chronic Lymphocytic Leukemia (Cll): A Prospective Analysis From the Cll14 Trial

Autologous Stem Cell Transplantation in First Remission Significantly Prolongs Progression-Free and Overall Survival in Mantle Cell Lymphoma

Effect of Dose Modifications on Response to Duvelisib in Patients With Relapsed/Refractory CLL/SLL in the Duo Trial

An Improved Benefit-Risk Profile of Duvelisib in Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Who Received 2 or More Prior Therapies

Samd14/Neurabin-I as BCR-Antigens of Primary Central Nervous System Lymphoma

Bendamustine (B), Followed by Obinutuzumab (G) and Venetoclax (A) in Patients With Chronic Lymphocytic Leukemia (Cll): Cll2-Bag Trial of the German CLL Study Group (Gcllsg)